Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials, Diabetes and Metabolism Journal (2019) Weight loss outcomes associated with semaglutide treatment for patients with overweight or obesity, JAMA (2022) Once-weekly semaglutide in adults with overweight or obesity, The New England Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension, Diabetes, Obesity and Metabolism (2022) Patient assistance program, Novo Nordisk APC: Find a compounder, Alliance for Pharmacy Compounding (2025) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice

A study by Marty and colleagues [41] confirmed that semaglutide significantly decreased ethanol intake and found that GLP-1 receptor antagonism by exendin 9-39 did not reverse the suppressing effects of semaglutide in male rats
When you drop pounds fastwhether from Ozempic, crash diets, or surgeryyour body can freak out
[DOI] [PubMed] [Google Scholar] 57.Laccourreye O, Werner A, Giroud J-P, Couloigner V, Bonfils P, Bondon-Guitton E